Mendus AB (publ) (IMMU.ST)
SEK 8.51
(-1.06%)
SEK 8.51
(-1.06%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 28.48 Million SEK | 851.15% |
| 2022 | 2.99 Million SEK | 49816.67% |
| 2021 | 6000.00 SEK | 0.0% |
| 2020 | - SEK | -100.0% |
| 2019 | 16.67 Million SEK | 0.0% |
| 2018 | - SEK | 0.0% |
| 2017 | - SEK | 0.0% |
| 2016 | - SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| 2012 | - SEK | -100.0% |
| 2011 | 5000.00 SEK | 0.0% |
| 2010 | - SEK | 0.0% |
| 2009 | - SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 2.78 Million SEK | -90.23% |
| 2024 Q2 | 625 Thousand SEK | -77.55% |
| 2023 Q3 | - SEK | 0.0% |
| 2023 Q4 | 28.48 Million SEK | 0.0% |
| 2023 Q2 | - SEK | 0.0% |
| 2023 FY | 28.48 Million SEK | 851.15% |
| 2023 Q1 | - SEK | 100.0% |
| 2022 Q2 | 35 Thousand SEK | -98.05% |
| 2022 Q3 | -152 Thousand SEK | -534.29% |
| 2022 FY | 2.99 Million SEK | 49816.67% |
| 2022 Q4 | -1.79 Million SEK | -1080.26% |
| 2022 Q1 | 1.79 Million SEK | 29800.0% |
| 2021 Q2 | - SEK | -100.0% |
| 2021 Q1 | 253 Thousand SEK | 0.0% |
| 2021 FY | 6000.00 SEK | 0.0% |
| 2021 Q4 | 6000.00 SEK | 0.0% |
| 2021 Q3 | - SEK | 0.0% |
| 2020 Q3 | - SEK | 0.0% |
| 2020 Q1 | - SEK | -100.0% |
| 2020 FY | - SEK | -100.0% |
| 2020 Q4 | - SEK | 0.0% |
| 2020 Q2 | - SEK | 0.0% |
| 2019 Q4 | 16.22 Million SEK | 7079.2% |
| 2019 Q1 | - SEK | 0.0% |
| 2019 Q2 | 76 Thousand SEK | 0.0% |
| 2019 Q3 | 226 Thousand SEK | 197.37% |
| 2019 FY | 16.67 Million SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 FY | - SEK | 0.0% |
| 2018 Q1 | - SEK | 0.0% |
| 2018 Q4 | - SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2017 FY | - SEK | 0.0% |
| 2017 Q4 | - SEK | 0.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 FY | - SEK | 0.0% |
| 2016 Q4 | - SEK | 0.0% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2015 Q4 | - SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2015 Q2 | - SEK | 0.0% |
| 2015 Q3 | - SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| 2014 Q1 | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| 2014 Q4 | - SEK | 0.0% |
| 2014 Q3 | - SEK | 0.0% |
| 2014 Q2 | - SEK | 0.0% |
| 2013 Q3 | - SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| 2013 Q2 | - SEK | 0.0% |
| 2013 Q1 | - SEK | 0.0% |
| 2013 Q4 | - SEK | 0.0% |
| 2012 Q4 | - SEK | 0.0% |
| 2012 Q3 | - SEK | 100.0% |
| 2012 Q2 | -2.00 SEK | 0.0% |
| 2012 Q1 | -2.00 SEK | 0.0% |
| 2012 FY | - SEK | -100.0% |
| 2011 FY | 5000.00 SEK | 0.0% |
| 2010 FY | - SEK | 0.0% |
| 2009 FY | - SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 58.1 Million SEK | 50.975% |
| Ziccum AB (publ) | 3.74 Million SEK | -660.262% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 615.99 Million SEK | 95.375% |
| Sprint Bioscience AB (publ) | 50.48 Million SEK | 43.573% |
| Genovis AB (publ.) | 158.23 Million SEK | 81.997% |
| Intervacc AB (publ) | 8.01 Million SEK | -255.421% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 4.37 Million SEK | -551.28% |
| Active Biotech AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 170.44 Million SEK | 83.286% |
| Bio-Works Technologies AB (publ) | 43.89 Million SEK | 35.103% |
| Aptahem AB (publ) | 2.63 Million SEK | -982.889% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | 1.03 Million SEK | -2652.367% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -36896.104% |
| Fluicell AB (publ) | 3.33 Million SEK | -753.415% |
| Saniona AB (publ) | 16.84 Million SEK | -69.163% |
| Lipigon Pharmaceuticals AB (publ) | 16.4 Million SEK | -73.627% |
| Biovica International AB (publ) | 7.29 Million SEK | -290.768% |
| Spago Nanomedical AB (publ) | 1.2 Million SEK | -2267.997% |
| AcouSort AB (publ) | 10.55 Million SEK | -169.993% |
| Xintela AB (publ) | 78 Thousand SEK | -36421.795% |
| Abliva AB (publ) | 137 Thousand SEK | -20693.431% |
| Egetis Therapeutics AB (publ) | 57.6 Million SEK | 50.543% |
| Karolinska Development AB (publ) | 2.01 Million SEK | -1314.449% |
| OncoZenge AB (publ) | 3000.00 SEK | -949466.667% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| 2cureX AB (publ) | 155 Thousand SEK | -18278.71% |
| CombiGene AB (publ) | 5.54 Million SEK | -413.824% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 1.2 Billion SEK | 97.64% |
| Camurus AB (publ) | 1.71 Billion SEK | 98.341% |
| Corline Biomedical AB | 25.03 Million SEK | -13.811% |
| IRLAB Therapeutics AB (publ) | 5.67 Million SEK | -401.708% |
| Isofol Medical AB (publ) | 721 Thousand SEK | -3851.04% |
| I-Tech AB | 120.86 Million SEK | 76.43% |
| Hansa Biopharma AB (publ) | 134.09 Million SEK | 78.756% |
| Cyxone AB (publ) | 5.14 Million SEK | -453.361% |
| ExpreS2ion Biotech Holding AB (publ) | 7.05 Million SEK | -304.071% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 10.66 Million SEK | -167.115% |
| Xspray Pharma AB (publ) | - SEK | -Infinity% |
| Elicera Therapeutics AB (publ) | 11.23 Million SEK | -153.667% |
| Nanologica AB (publ) | 1.44 Million SEK | -1874.151% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 53 Thousand SEK | -53649.057% |
| BioInvent International AB (publ) | 71.46 Million SEK | 60.136% |
| Alzinova AB (publ) | 270 Thousand SEK | -10450.741% |
| Oncopeptides AB (publ) | 35.22 Million SEK | 19.117% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -1847.137% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 2.82 Million SEK | -909.461% |
| Simris Alg AB (publ) | 4.35 Million SEK | -554.272% |
| Diamyd Medical AB (publ) | 130 Thousand SEK | -21813.077% |
| Xbrane Biopharma AB (publ) | 238.72 Million SEK | 88.067% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 23 Thousand SEK | -123756.522% |